Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 5
Submit an article Journal homepage
214
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Adequacy of peripheral blood stem cell mobilization in patients with relapsed B-cell non-Hodgkin lymphoma treated with bendamustine

Andrew IliffDepartment of Medicine, University of Kansas Medical Center, Kansas City, KS, USA,
,
Clint DivineDivision of Cellular Therapeutics and Hematologic Malignancies, University of Kansas Medical Center, Westwood, KS, USA, and
,
Francisco DiazDepartment of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA
,
Omar AljitawiDivision of Cellular Therapeutics and Hematologic Malignancies, University of Kansas Medical Center, Westwood, KS, USA, and
,
Sunil AbhayankarDivision of Cellular Therapeutics and Hematologic Malignancies, University of Kansas Medical Center, Westwood, KS, USA, and
,
Joseph McGuirkDivision of Cellular Therapeutics and Hematologic Malignancies, University of Kansas Medical Center, Westwood, KS, USA, and
&
Siddhartha GangulyDivision of Cellular Therapeutics and Hematologic Malignancies, University of Kansas Medical Center, Westwood, KS, USA, and Correspondence[email protected]
 show all
Pages 1189-1190 | Published online: 12 Oct 2015

References

  • Clark R, Brammer C. Previous treatment predicts the efficiency of blood progenitor cell mobilization: validation of a chemotherapy scoring system. Bone Marrow Transpl 1998; 22: 859–863.
  • Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer 2010; 116: 106–114.
  • Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol 2005; 23: 3383–3389.
  • Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008; 26: 204–210.
  • Gil L, Kazmierczak M, Kroll-Balcerzak R, et al. Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma. Med Oncol 2014; 31: 944.
  • Burchardt CA, Brugger W, Maschmeyer G, et al. Peripheral blood stem cell mobilization after bendamustine containing chemotherapy in indolent lymphomas is possible. Results from the phase III Study of B-R vs. CHOP-R (NHL 1-2003 trial) of the Stil (Study group indolent Lymphomas, Germany). Blood 2009; 114: 2679.
  • Abhyankar S, DeJarnette S, Aljitawi O, et al. A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transpl 2012; 47: 483–487.
  • Merchionne F, Quintana G, Gaudio F, et al. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis. Leuk Res 2014; 38: 1446–1450.
  • Visani G, Malerba L, Stefani PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011; 118: 3419–3425.
  • Mark TM, Reid W, Niesvizky R, et al. A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma. Biol Blood Marrow Transpl 2013; 19: 831–837.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.